MLchartDataset catalogue

Truqap

Term · Oncology and biomedicine · MLC-T-ONC-008931

A drug used with fulvestrant to treat adults with hormone-receptor positive, HER2-negative breast cancer that has spread and has an abnormal PIK3CA, AKT1, or PTEN gene. It is used in patients whose cancer came back or got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Truqap blocks a protein called AKT, which is involved in cell signaling, cell growth, and cell survival. Blocking this protein may help keep cancer cells from growing and may kill them. Truqap is a type of kinase inhibitor. Also called capivasertib.

Table 1. Record
IdentifierMLC-T-ONC-008931
FieldOncology and biomedicine
Synonymscapivasertib
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-008931",
  "term": "Truqap",
  "field": "Oncology and biomedicine",
  "definition": "A drug used with fulvestrant to treat adults with hormone-receptor positive, HER2-negative breast cancer that has spread and has an abnormal PIK3CA, AKT1, or PTEN gene. It is used in patients whose cancer came back or got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Truqap blocks a protein called AKT, which is involved in cell signaling, cell growth, and cell survival. Blocking this protein may help keep cancer cells from growing and may kill them. Truqap is a type of kinase inhibitor. Also called capivasertib.",
  "synonyms": [
    "capivasertib"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/truqap/"
}

Record 16,772 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.